Citrate-Buffered, Magnesium-Enriched Dialysate on Calcification Propensity in Hemodialysis Patients – The CitMag Study

This is the authors' abstract. We don't add key points for this paper.

IntroductionSerum calcification propensity (T50 time) is associated with mortality in dialysis patients. Several solitary interventions improve T50, but whether a combination of interventions yields further increases in T50 is unknown. We hypothesized that a combination of two interventions, namely increasing magnesium concentration while simultaneously substituting acetate for citrate in the dialysis fluid, leads to increases in T50 values.MethodsIn a randomized, controlled trial, 60 chronic hemodialysis patients were allocated to either continue on standard (S) dialysate (3 mmol/l acetate, 0.5 mmol/l magnesium) or a sequence of magnesium-enriched (Mg0.75) dialysate (3 mmol/l acetate, 0.75 mmol/l magnesium) for 2 weeks followed by combination treatment using citrate-buffered, magnesium-enriched (Cit+Mg0.75) dialysate (1 mmol/l citrate, 0.75 mmol/l magnesium) for 3 weeks. The primary endpoint was the difference in T50 times between the S group and the Cit+Mg0.75 group.ResultsThere was no significant difference in T50 time between the S group compared to the Cit+Mg0.75 group (236 ± 77 vs. 265 ± 97 minutes, p=0.23). The size of secondary calciprotein particles (CPP-2Rh) did not differ between the S group and the Cit+Mg0.75 group (294 ± 95 vs. 309 ± 91 nm, p=0.56). In longitudinal analyses, serum magnesium concentrations increased from 1.07 ± 0.17 to 1.24 ± 0.17 mmol/l with the Mg0.75 dialysate (p<0.0001) but decreased again to 1.19 ± 0.16 mmol/l with the Cit+Mg0.75 dialysate (p<0.0001).ConclusionThe combination of citrate-buffer with increased magnesium concentration in dialysate does not improve T50.